Pegcantratinib

N/A

Report date: 2023/12/10 20:00:33
NME

Base Information

Drug NamePegcantratinib
Drug Alias NameCT 327SNA-120K-252a-PEG2KPegylated K252ACT 301/P
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNerve growth factor receptor Trk-A antagonists
TargetsNerve growth factor receptor Trk-A
Therapy Area/IndicationsPsoriasisPruritusDermatitis, Atopic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesDenmark +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCephalon
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSienna Biopharmaceuticals IncCreabilis Sa
Active IndicationsN/A
Inactive IndicationsPsoriasisPruritusDermatitis, Atopic +[4] 

Other Information

ATC CodeN/A
Related LinksN/A